Financial News Feed

Weaker Buy Today AKBA ranks #1788 as BUY CANDIDATE. Stronger Buy
Today AKBA ranks #1788 as BUY CANDIDATE.

AKBA stock Akebia Therapeutics

AKBA stock
Akebia Therapeutics

The stock of Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a huge mover today! The stock increased 2.45% or $0.2 during the last trading session, reaching $8.37. About 1.02 million shares traded. Akebia ...

Read more

Studying shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA), we note that performance has not been great over the last year. During that time, shares have slid -31.46%. The investing community will be ...

Read more

Nantahala Capital Management Llc decreased Akebia Therapeutics Inc (Call) (AKBA) stake by 51.35% reported in 2018Q4 SEC filing. Nantahala Capital Management Llc sold 437,000 shares as Akebia Therapeut...

Read more

Traders may be focused on various technical signals on shares of Akebia Therapeutics (AKBA). Today we have focused on the 50-day MA vs Price signal. During a recent scan, we have seen that the current...

Read more

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Akebia Therapeutics (AKBA), with a price target of ... The post Akebia Therapeutics (AKBA) Gets a Buy Rating fr...

Read more

AKBA earnings call for the period ending December 31, 2018....

Read more

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2018 Earnings Conference Call March 18, 2019, 16:30 ET Company Participants John Butler - CEO, President & Direct...

Read more

Akebia Therapeutics Inc. (NASDAQ:AKBA) and Celsion Corporation (NASDAQ:CLSN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects suc...

Read more

Akebia Therapeutics Inc. (NASDAQ:AKBA) and Xenetic Biosciences Inc. (NASDAQ:XBIO) compete against each other in the Biotechnology sector. We will contrast them and contrast their dividends, analyst re...

Read more

Akebia Therapeutics Inc. (NASDAQ:AKBA) and Aduro BioTech Inc. (NASDAQ:ADRO), are influenced by compare since they are both players in the Biotechnology. These...

Read more

If you want to know who really controls Akebia Therapeutics, Inc. (NASDAQ:AKBA), then you’ll have to look at the makeup of its share registry. Insiders often own a large chunk Read More......

Read more

Van Cleef Asset Managementinc increased its stake in Paychex Inc (PAYX) by 3.5% based on its latest 2018Q4 regulatory filing with the SEC. Van Cleef Asset Managementinc bought 4,705 shares as the comp...

Read more

AKEBIA THERAPEUTICS, INC. (NASDAQ:AKBA) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Akebia Therapeutics, Inc. ExhibitEX-99.1 2 d685250dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 A...

Read more

Company shares of Akebia Therapeutics (AKBA) have seen the Rank Correlation Indicator climb higher over the past 3 trading days, suggesting that it could be nearing a turning point if the reading cros...

Read more

Akebia Therapeutics Inc. (NASDAQ:AKBA) and Therapix Biosciences Ltd. (NASDAQ:TRPX), both competing one another are Biotechnology companies. We will compare their profitability, institutional ownership...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank